Related Experiment Videos
Itraconazole pharmacokinetics in patients with renal dysfunction
J Boelaert1, M Schurgers, E Matthys
1Renal Unit, Algemeen Ziekenhuis St. Jan, Brugge, Belgium.
Antimicrobial Agents and Chemotherapy
|October 1, 1988
Summary
This study investigated itraconazole pharmacokinetics in patients with kidney issues. Renal dysfunction and dialysis did not significantly alter itraconazole levels, but more research is needed.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Pharmacy
Background:
- Itraconazole is an antifungal medication.
- Renal dysfunction can affect drug pharmacokinetics.
- Optimal dosing in renal impairment requires understanding drug behavior.
Purpose of the Study:
- To evaluate the single-dose pharmacokinetics of oral itraconazole.
- To assess the impact of renal dysfunction and dialysis on itraconazole levels.
Main Methods:
- Single oral dose of 200 mg itraconazole administered.
- Pharmacokinetic profiles analyzed in uremic patients, hemodialysis patients, and continuous ambulatory peritoneal dialysis patients.
- Plasma drug concentrations measured over time.
Main Results:
- Observed wide intersubject variation in plasma concentration-versus-time profiles.
- No statistically significant effect of renal dysfunction or dialysis modality on itraconazole pharmacokinetics was demonstrated.
Conclusions:
- Current data suggest renal impairment and dialysis may not significantly alter itraconazole pharmacokinetics.
- Further studies with larger patient cohorts are necessary to confirm these preliminary findings and guide dosing recommendations.